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Neurobiology of Disease

NADPH Oxidase 1 Mediates ␣-Synucleinopathy in
Parkinson’s Disease
Ana Clara Cristóvão,1,2,3 Subhrangshu Guhathakurta,1 Eugene Bok,1 Goun Je,1 Seung Don Yoo,1,5 Dong-Hee Choi,4
and Yoon-Seong Kim1
1

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32827, 2Health Sciences Research Center,
University of Beira Interior, Covilhã 6200-506, Portugal, 3Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, University of
Coimbra, Coimbra 3400-516, Portugal, 4Department of Medical Science, Konkuk University School of Medicine and Center for Neuroscience, SMART
Institute of Advanced Biomedical Science, Konkuk University, Seoul 143-701, South Korea, and 5Department of Physical Medicine and Rehabilitation,
School of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea

Accumulation of misfolded ␣-synuclein is the pathological hallmark of Parkinson’s disease (PD). Nevertheless, little is known about the
mechanism contributing to ␣-synuclein aggregation and its further toxicity to dopaminergic neurons. Since oxidative stress can increase
the expression and aggregation levels of ␣-synuclein, NADPH oxidases (Noxs), which are responsible for reactive oxygen species generation, could be major players in ␣-synucleinopathy. Previously, we demonstrated that Nox1 is expressed in dopaminergic neurons of the
PD animal models as well as postmortem brain tissue of PD patients, and is responsible for oxidative stress and subsequent neuronal
degeneration. Here, using paraquat (PQ)-based in vitro and in vivo PD models, we show that Nox1 has a crucial role in modulating the
behavior of ␣-synuclein expression and aggregation in dopaminergic neurons.
We observed in differentiated human dopaminergic cells that Nox1 and ␣-synuclein expressions are increased under PQ exposure.
Nox1 knockdown significantly reduced both ␣-synuclein expression and aggregation, supporting the role of Nox1 in this process.
Furthermore, in rats exposed to PQ, the selective knockdown of Nox1 in the substantia nigra, using adeno-associated virus encoding
Nox1-specific shRNA, largely attenuated the PQ-mediated increase of ␣-synuclein and ubiquitin expression levels as well as ␣-synuclein
aggregates (proteinase K resistant) and A11 oligomers. Significant reductions in oxidative stress level and dopaminergic neuronal loss
were also observed. Our data reveal a new mechanism by which ␣-synuclein becomes a neuropathologic protein through Nox1-mediated
oxidative stress. This finding may be used to generate new therapeutic interventions that slower the rate of ␣-synuclein aggregation and
the progression of PD pathogenesis.

Introduction
Despite there being numerous studies performed to decipher the
pathogenesis of Parkinson disease (PD), the exact cause rendering this pathology remains unknown, indicating a multifactorial
etiology behind the disease. To understand the mechanism of
neuronal death occurring in PD, it is important to solve the
enigma of plausible interaction between different factors, like
oxidative stress and genetic factors, which may culminate in dopaminergic neurodegeneration.
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␣-Synuclein, the principal component of Lewy bodies, has
been reported as a cause of PD (Beyer et al., 2009; Cookson,
2009). The encoding gene of ␣-synuclein, SNCA, is the first gene
where a strong correlation between its functional mutations and
familial form of PD was demonstrated (Polymeropoulos et al.,
1997; Krüger et al., 1998; Zarranz et al., 2004). While the molecular mechanism underlying its toxic effects on the nigrostriatal
system is largely unknown, the aberrant expression and aggregation of ␣-synuclein have been considered as potential causes involved in neuronal toxicity (Vekrellis et al., 2011).
Evidence suggested that paraquat (PQ) is a specific neurotoxin for dopaminergic neurodegeneration in the substantia
nigra (SN) (Brown et al., 2006; Gatto et al., 2010), and the structure of PQ suggests that increased oxidative stress might be the
reason of its toxicity. The SN of PD patients’ postmortem brain
tissues showed high oxidative stress with an increase in lipid peroxidation (Dexter et al., 1989), oxidative damages in DNA
(Zhang et al., 1999) and protein (Alam et al., 1997), and decreased glutathione levels (Sofic et al., 1992). Evidence has demonstrated that the NADPH oxidase (Nox) complexes also play a
role in generating reactive oxygen species (ROS) beside mitochondria, and are implicated in several pathologic conditions in
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CNS (Sorce and Krause, 2009). Our previous results showed that
Nox1, an isoform of the Nox family, has a role in PQ-mediated
dopaminergic neuronal cell death both in vivo and in cell cultures
(Cristóvão et al., 2009). Recently, we have demonstrated that
Nox1/Rac1 is activated in dopaminergic neurons following
6-hydroxydopamine (6-OHDA) treatment as well, causing oxidative stress and consequential neuronal death (Choi et al.,
2012). Since oxidative stress is generally considered as a factor
affecting ␣-synuclein aggregation (Krishnan et al., 2003), PQmediated oxidative stress was also shown to increase ␣-synuclein
aggregation and expression levels in the SN of mice (ManningBog et al., 2002). Halting the expression levels of ␣-synuclein in a
mouse model of PD was shown to be beneficial with reduced
progression of neurodegeneration (Nuber et al., 2008). Understanding how ␣-synuclein expression and aggregation is regulated will provide us with targets that ultimately may be used to
control and reduce the progression of certain aspects of the disease phenotype.
In the current study, we have investigated the effect of Nox1derived ROS on the expression and aggregation of ␣-synuclein in
the SN of rats exposed to PQ. We demonstrated that PQ-treated
rats show noticeable ␣-synuclein increased expression and aggregation, which were clearly reduced in Nox1 knockdown.

Materials and Methods
Cell cultures
ReNcell VM culture method. For the in vitro experiments on human dopaminergic neurons, we have used human mesencephalic neuronal progenitor cell line available from Millipore (catalog number SCC008). The
specialty of these cells is that they are isolated from fetal human ventral
mesencephalic region and subsequently immortalized by introduction of
v-myc. The cells can readily differentiate into dopaminergic neurons
upon withdrawal of growth factors (Millipore). We have followed the
culture method as indicated by the company with little modifications.
Briefly, the cells were allowed to grow on laminin-coated (20 g/ml)
dishes in DMEM/F12-containing medium with B27 supplement, glutamax, heparin (10 U/ml), and gentamicin (50 g/ml). This medium is
called maintenance medium. Cell division was allowed by addition of the
two growth factors in the medium viz., basic fibroblast growth factor
(bFGF) and epidermal growth factor (EGF), both at a concentration of
20 ng/ml. To induce differentiation, both growth factors were removed
from the media and the cells were allowed to differentiate for 14 d with
changing medium every alternate day before harvesting or any treatment. After differentiation, cells were treated with 800 M or 1000 M PQ
for 8 and 24 h.
Immortalized rat mesencephalic dopaminergic cell (N27 cells) culture.
The N27 cells were grown in RPMI 1640 medium containing 10% fetal
bovine serum (FBS), 100 U penicillin, and 50 g/ml streptomycin, in a
humidified atmosphere of 5% CO2 at 37°C. N27 cultures were prepared
for experiments by plating the cells on polystyrene tissue culture dishes at
a density of 0.5 ⫻ 10 5 cells/well in 24-well culture plates with glass coverslip and at 1.5 ⫻ 10 5 cells/well in 6-well culture plates.

Animals and treatment paradigm
The experiments were performed on rats, in accordance with the National Institutes for Health Guide for the Care and Use of Laboratory
Animals. All procedures were approved by the local Animal Care and Use
Committee. Male Wistar rats (8 –10 weeks; Charles River) were maintained in a temperature/humidity-controlled environment under a 12 h
light/dark cycle with ad libitum access to food and water. As depicted in
Figure 7A, each animal received four intraperitoneal injections, separated by 1 d, of either vehicle (saline) or PQ (10 mg/kg body weight; b.w.),
according to a previously published dose (Manning-Bog et al., 2002;
Harraz et al., 2008; Cristóvão et al., 2009). All animals were weighed at
day 1 and 12. In the studies using the paradigm depicted in Figure 7A, 4
weeks before starting PQ intraperitoneal injection, animals were stereotaxically injected with various viral constructs at the right SN using the
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following coordinates: mediolateral, ⫹2.0; anteroposterior, ⫺5.3; dorsoventral, ⫺6.8. Animals were organized into four groups: vector ⫹ vehicle: stereotaxically injected with adeno-associated virus (AAV) particles
containing a green fluorescent protein (GFP) vector (vector) and then
intraperitoneally injected with saline (vehicle) (n ⫽ 10); vector ⫹ PQ:
stereotaxically injected with vector and then intraperitoneally injected
with PQ (n ⫽ 10); shNox1 ⫹ PQ: stereotaxically injected with AAV
particles harboring Nox1 shRNA and then intraperitoneally injected
with PQ (n ⫽ 10); shNox1 ⫹ vehicle: stereotaxically injected with Nox1
shRNA and then intraperitoneally injected with vehicle (n ⫽ 8). AAV
containing GFP vector was used as a negative control. Five days after the
last PQ intraperitoneal injection, animals were killed. For Western blot
analysis, brains were collected and total protein lysates from SN were
prepared. For immunohistochemical analysis, animals were intracardially perfused before collecting the brains.

Construction of shRNA delivery vector U6-CMV-EGFP/pAAV
(AAV-Nox1 shRNA) and preparation of rAAV2 containing Nox1
shRNA
U6 promoter-driven shRNA expression system was established in AAV
serotype 2 (AAV2) vector. Enhanced GFP (EGFP) expression is separately controlled by a cytomegalovirus (CMV) promoter as a marker for
the transduction efficiency. Rat Nox1 shRNA was designed based on the
siRNA sequence, which efficiently knocked down Nox1 expression in
N27 cells (Cristóvão et al., 2009).
The plasmid DNA vector only or AAV-Nox1 shRNA was cotransfected
with plasmids pHelper and pAAV-RC to HEK293 AAV cells using a
standard calcium phosphate method. After 72 h, the cells were harvested
and crude rAAV vector solutions were obtained by repeated freeze/thaw
cycles. The cleared crude lysate was then applied on a heparin column.
After the total lysate pass through the column, the matrix was washed
twice with 25 ml of PBS with low NaCl (pH7.4, 0.1 M NaCl). The virus was
then eluted with 15 ml of PBS with high NaCl (PBS; pH 7.4, 0.4 M NaCl).
The elute was concentrated to ⬃1 ml with a Millipore Biomax-100K
NMWL filter device (UFV2BHK40) by centrifugation 4000 rpm, 15– 40
min. To adjust the NaCl concentration to physiological levels, the filter
device was refilled with PBS, pH 7.4, and the virus was concentrated to
250 –300 l. After removal of the virus-containing solution, the membrane of the filter device was washed three times with PBS, pH 7.4, which
was added to the main part of the recombinant AAV2. The fractions
containing high-titer rAAV vectors were collected and used for injection
into animals. The number of rAAV genome copies was semiquantified by
PCR within the CMV promoter region using primers 5⬘-GACGTCAATA
ATGACGTATG-3⬘ and 5⬘-GGTAATAGCGATGACTAATACG-3⬘. The
final titers were 6.4 ⫻ 10 11 genomes/l (rAAV2-vector) and 5.5 ⫻ 10 11
genomes/l (rAAV2-NOX-1 shRNA). Each animal received 16.5 ⫻
10 11genomes of the respective rAAV-vector.

Construction of shRNA delivery vector pLVX-shRNA2-zsGreen1/
LVX (Lenti-Nox1 shRNA) and preparation of lentivirus
containing Nox1 shRNA
The same Nox1 shRNA used for AAV2 construct was cloned into a
pLVX-shRNA2 vector containing zsGreen1 (Clontech). To make lentiviral particles, ViraPower Lentiviral Expression System (Invitrogen) was
used. The three packaging plasmids pLP1, pLP2, and pLP/VSVG, were
individually purified from the mixture based on the pattern of restriction
enzyme digestion. pLVX-shRNA2-rNox1 and the three packaging plasmids were cotransfected to Lenti-X 293T cells (Clontech) according to
the Xfect transfection reagent protocol (Clontech). For 6-well plates, 8
g of each plasmid was mixed in a 1:1:1:1 ratio in 100 l of Xfect polymer
buffer and then added to the cells. After 48 h, the viral-containing medium was harvested and centrifuged briefly at 500 ⫻ g for 10 min to
remove cellular debris and supernatant recovered and kept at ⫺80°C
until used.

Transient transfection of ␣-synuclein tagged with FLAG (N
terminal) and Myc (C terminal)

Human ␣-synuclein was cloned into the p3xFLAG-myc-CMV-23 expression vector (Sigma) for N- and C-terminal tagging with FLAG and
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Figure 1. Increases in ␣-synuclein and Nox1 in human dopaminergic neurons exposed to PQ. A, Characterization of human ventral mesencephalic neuronal progenitor cell line, ReNcell VM, after
differentiation (human dopaminergic neurons). Left, Depicts representative photomicrographs of TH, Tuj1, and DAPI immunostaining of ReNcell VM after 14 days differentiation. Right, Displays the
expression of TH protein in ReNcell VM, before and after differentiation. B, ␣-Synuclein levels in differentiated human dopaminergic cells exposed to PQ. Left, Shows ␣-synuclein immunoreactivity
(red). Right, Represents ␣-synuclein protein levels in immunoblot. C, Nox1 levels in differentiated human dopaminergic cells exposed 8 h to PQ. Left, Shows Nox1 immunoreactivity (green). Right,
Illustrates Nox1 protein levels in immunoblot. ␤-Actin was used as an internal control. Und, undifferentiated; Diff, differentiated; Ctr, control; PQ, paraquat. Scale bars: 50 m.
Myc, respectively. For transient overexpression of tagged ␣-synuclein,
N27 cells were plated onto 24-well plates with coverslips at 0.5 ⫻ 10 5 cells
per well 1 d before transfection. The next day, cells were transiently
transfected with FLAG-WTsyn-myc. Briefly, 1 g of plasmid DNA was
mixed with 6 l of Lipofectamine 2000 (Invitrogen) in 100 l of OptiMEM for 20 min before addition in the culture. After 6 h of incubation,
the culture medium was changed and 100 l of Nox1 shRNA/LVX viral
particle was added to each well. Cells were maintained for an additional
36 h before treatment with 800 M or 1000 M PQ for 8 and 24 h.

Western blot
For Western blot, brain tissues were lysed on ice in radioimmunoprecipitation assay buffer containing 50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 2
mM sodium orthovanadate, 1% Nonidet-P40 (NP-40), 0.5% sodium deoxycholate, and 0.1% SDS, containing 1% of a protease inhibitor mixture
(AEBSF, pepstatinA, E-64, bestatin, leupeptin, and aprotinin). The soluble fraction was obtained and equal amounts of cell lysate protein were
loaded in each lane of a 12% SDS-PAGE or 4/10% to 20% polyacrylamide
gel. After electrophoresis and transfer onto a polyvinylidene difluoride
(PVDF) membrane, specific protein bands were detected using ap-

propriate primary antibodies (rabbit anti-Nox1, rabbit anti-␣synuclein, mouse anti-Ubiquitin, mouse anti-tyrosine hydroxylase
(TH), and mouse anti-␤-actin) and secondary antibodies conjugated
to alkaline phosphatase or hydrogen peroxidase (anti-rabbit or antimouse) followed by Enhanced Chemifluorescence (ECF) detection or
Enhanced Chemiluminescence (ECL).

Dot blot analysis
For dot blot, brain tissues were homogenized in a buffer containing
0.32 M sucrose, 1 mM NaHCO3, 1 mM MgCl2, 0.5 mM CaCl2, and 1% of a
protease inhibitor mixture (AEBSF, pepstatinA, E-64, bestatin, leupeptin, and aprotinin). The soluble fraction was obtained by centrifugation
at 1000 ⫻ g and 5 l of each sample, containing the same amount of
protein, was spotted in a PVDF membrane. Membrane was air dried for
4 h and blocked overnight at 4°C in 5% nonfat dry milk TBST (10 mM
Tris-HCl, pH 7.8, 100 mM NaCl, 0.05% Tween 20) solution. Protein
spots were detected using the primary antibody, rabbit anti-A11oligomer
(0.5 g/ml) from Invitrogen, and secondary antibody conjugated to hydrogen peroxidase (anti-rabbit) followed by ECL detection.
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Figure 2. PQ induces increases of ␣-synuclein expression and aggregation in N27 cells, an event prevented by Nox1 knockdown. A, Representative immunoblot and quantitative analysis of
␣-synuclein protein levels. ␣-Synuclein protein was determined in total lysates of N27 cells exposed to PQ or control. ␤-Actin was used as an internal control. PQ significantly increased ␣-synuclein
protein levels, which were quantified using Quantity One software and normalized against ␤-actin. B, Photomicrographs of aggregated ␣-synuclein immunoreactivity (red) in control and
PQ-treated cells. The bottom shows higher magnification of respective boxed areas in the top. C, ␣-Synuclein fluorescence immunostaining of N27 cells incubated with Nox1 shRNA/LVX
(shNox1-ZsGreen) viral particles for 36 h and then exposed to 800 M PQ. shNox1-ZsGreen-infected cells were identified by green fluorescence (ZsGreen) in cells. D, Quantification of the cells
depicting the bright, punctuated fluorescence, like the ones indicated with arrowheads in B and C. More than 30 assigned fields were analyzed in each independent experiment and in average the
minimum number of total cells counted per condition was 700 cells. Data are shown as the mean ⫾ SEM. Statistical analysis was performed using one-way ANOVA or two-way ANOVA, followed by
Bonferroni’s multiple-comparison test; *p ⬍ 0.05, **p ⬍ 0.01, and ***p ⬍ 0.001. Arrowheads specify cells with aggregated ␣-synuclein pattern, and the arrow indicates N27 cells showing
double-staining for shNox1-ZsGreen and ␣-synuclein. Ctr, control; PQ, paraquat. Scale bars: 10 m.

Measurement of oxidized proteins
The levels of protein carbonyl were measured in protein extracts from the
SN tissues, using the OxiSelect Protein Carbonyl Immunoblot Kit (Cell
Biolabs), according to the manufacturer’s instructions, with small modifications. Briefly, 5% nonfat dry milk/PBST was used as blocking solution and antibody buffer, and the membrane was blocked for 1 h and
incubated with the primary antibody overnight. Detection was performed using ECL.

Immunocytochemistry
After each respective treatment, cells were fixed in 4% paraformaldehyde
(PFA) for 20 min and permeabilized with 0.1% Triton X-100 in PBS for
10 min. Blocking was performed by incubation with 20% goat or donkey
serum in PBS containing 0.1% Tween 20 for 90 min at room temperature. The cells were then incubated for 120 min at room temperature with
the following primary antibodies, according to the aim of the experiment: goat anti-Nox1 (1:50), rabbit anti-TH (1:10,000), mouse anti-Flag
(1:150), mouse anti-␣-synuclein (1:150), and rabbit anti-A11 (2.5 g/

ml). After washing, cells were incubated for 120 min with the appropriate
secondary antibodies conjugated to Alexa Fluor 647 or Alexa Fluor 488
(1:1000). For nuclear visualization coverslips were incubated with 2 M
Hoechst for 10 min. For quantification of Flag ⫹ and ␣-synuclein ⫹ cells,
⬎30 different fields per coverslip were analyzed on a Nikon inverted
fluorescent microscope under a 20⫻ and 40⫻ magnification.

Immunohistochemistry
Following perfusion with saline and 4% PFA in PBS, brains were removed, and forebrain and midbrain blocks were immersion fixed in 4%
PFA and cryoprotected in sucrose. Serial coronal sections (40 m) were
cut on a cryostat, collected in cryopreservative solution, and stored at
⫺20°C. For immunolabeling studies, sections were incubated at room
temperature with blocking solution for 1 h (5% FBS and 0.3% Triton
X-100 in PBS, pH 7.5) and then with primary antibodies overnight.
Finally, sections were incubated with secondary antibodies in blocking
solution at room temperature for 1 h. The primary antibodies used were
mouse anti-TH (1:10,000), rabbit anti-Nox1 (1:500), goat anti-4-HNE

Cristóvão et al. • Nox1 Contribution for ␣-Synucleinopathy

J. Neurosci., October 17, 2012 • 32(42):14465–14477 • 14469

Products), a DEI-750 video camera (Meyer Instruments), a Dell Dimension 4300 computer
(Dell), and the Stereo Investigator (v. 4.35)
software program (Microbrightfield).

Proteinase K digestion of cells and tissues
for ␣-synuclein aggregates detection
Immunocytochemistry for proteinase K (PK)resistant ␣-synuclein was performed based on
a methodology reported previously (Neumann
et al., 2002), with some modifications. Briefly,
fixed cells were permeabilized with 0.1%
Tween 20 and then digested for 30 min at 37°C
with PK (10 g/ml). PK was inactivated with
3 M guanidine thiocyanate in 10 mM Tris-HCl
solution for 10 min. Between each step, cells
were washed gently three times with PBS. Cells
were then incubated for 60 min with blocking
solution containing 10% donkey serum followed by an overnight incubation with mouse
anti-␣-synuclein antibody (1:150). The day after, cells were incubated with secondary antibodies conjugated to Alexa Fluor 647 donkey
anti-mouse for 60 min and with 2 M
Hoechst solution for 10 min. For PK-resistant
␣-synuclein evaluation in rat SN, 40 m sections from 4% PFA fixed tissues were washed
twice in distillated water with 0.1% Tween 20,
and then incubated for 30 min in TBST. The
tissues were incubated for 90 min at 55°C with
50 g/ml PK in TBST and further washed three
times in TBS. PK was denatured by incubating
the tissues in a 3 M guanidine thiocyanate in 10
mM Tris-HCl solution for 10 min. Sections
were incubated with blocking solution for 1 h
(TBST with 0.2% casein) and then with rabbit
anti-␣-synuclein (1:150) at 4°C overnight. Finally, sections were incubated with biotinylated anti-rabbit IgG (1:200 blocking solution)
at room temperature for 1 h. The staining procedure was performed as indicated by the manufacturer of the Vectastain ABC kit and the
reaction product visualized using DAB reagent
in TBS containing 0.02% H2O2.

Data analysis and statistics

Figure 3. PQ increases levels of PK-resistant ␣-synuclein and A11 oligomer formation in N27, which is reversed by Nox1
knockdown. A, PK-resistant ␣-synuclein immunoreactivity in control and PQ-treated N27 cells. The bottom (scale bars: 10 m)
shows higher magnification of respective boxed areas shown in the top (scale bars: 50 m). B, C, A11 immunoreactivity of control
or PQ-treated N27 cells (B) and in N27 cells incubated with Nox1 shRNA/LVX (shNox1-ZsGreen) viral particles for 36 h exposed to
800 M PQ (C). Scale bars: (for B, C), 10 m.
(1:700), mouse anti-ubiquitin (1:250), rabbit anti-␣-synuclein (1:150),
and rabbit anti-A11 oligomers (2.5 g/ml). The secondary antibodies
were biotinylated anti-rabbit IgG, anti-goat IgG, or anti-rat IgG (1:200).
The staining procedure was performed as indicated by the manufacturer
of the Vectastain ABC kit and the reaction product visualized using 3,3⬘diaminobenzidine (DAB) reagent in TBS containing 0.02% H2O2. The
numbers of TH-immunoreactive cells in the SN were counted using an
optical fractionator. Analysis was performed using a system consisting of
a Nikon Eclipse E600 microscope (Morrell Instruments) equipped with a
computer-controlled LEP BioPoint motorized stage (Ludl Electronic

Statistical analysis was performed with GraphPad Prism v.5 (GraphPad Software). Data are
expressed as percentages of values obtained
in control conditions, and are presented as
mean ⫾ SEM of at least four animals (in vivo
studies). Statistical analyses were performed
using the one-way ANOVA or two-way
ANOVA followed by Bonferroni’s multiplecomparison test, or using Student’s t test. Values of p ⬍ 0.05 were considered significant.

Reagents

FBS and gentamycin were purchased from Invitrogen BRL. Phenylmethylsulfonyl fluoride,
NP-40, SP600125, Brij35, and bupropion were
purchased from Sigma Chemicals. Mouse anti-TH was obtained from
Transduction Laboratories; rabbit anti-Nox1, rabbit anti-␣synuclein, and mouse anti-ubiquitin were obtained from Santa Cruz
Biotechnology; and mouse anti-␣-synuclein from BD Transduction Laboratories. Goat anti-4-HNE and EGF were purchased from Millipore
Bioscience Research Reagents. Rabbit anti-A11, Alexa Fluor 488 or Alexa
Fluor 647, Hoechst 33342, Lipofectamine, ViraPower Lentiviral Expression System, 10 –20% SDS polyacrylamide gel and 10 –20% tricine gel,
laminin, glutamax, DMEM/F12, and B27 supplement were purchased
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Figure 4. Nox1 knockdown inhibits aggregation of overexpressed WT ␣-synuclein in N27 cells induced by PQ. A, Representative pictures of flag-tagged WT ␣-synuclein immunoreactivity (red)
in control and PQ-treated cells. Scale bars: (for top), 50 m; (for bottom), 10 m. B, Flag-tagged WT ␣-synuclein fluorescence immunostaining of N27 cells incubated with Nox1 shRNA/LVX
(shNox1-ZsGreen) viral particles and exposed to 800 M PQ. shNox1-ZsGreen-infected cells were identified by green fluorescence (ZsGreen) in cells. Scale bar, 10 m. C, Quantification of the bright,
punctuated fluorescent cells, indicated with arrowheads in A and B. More than 20 assigned fields were analyzed in each independent experiment and in average the minimum number of total cells
counted per condition was 400 cells. Data are shown as the mean ⫾ SEM. Statistical analysis was performed using one-way ANOVA or two-way ANOVA, followed by Bonferroni’s multiplecomparison test; **p ⬍ 0.01 and ***p ⬍ 0.001. Arrowheads specify cells with aggregated ␣-synuclein pattern, and arrows indicate N27 cells depicting double-staining for shNox1-ZsGreen and
␣-synuclein-flag. Ctr, control; PQ, paraquat.

from Invitrogen. ECF Western Blotting kit was obtained from GE Healthcare Bioscience. Vectastain ABC kit, biotinylated anti-rabbit, anti-mouse
IgG, or anti-goat IgG were from Vector Laboratories. Taq polymerase was
from Roche Applied Science. PQ, protease inhibitor mixture (AEBSF, aprotinin, bestatin hydrochloride, E-64-[N-(trans-epoxysuccinyl)-L-leucine
4-guanidinobutylamide], leupeptin, pepstatin A), heparin, PK, and guanidine thiocyanate were from Sigma-Aldrich. bFGF was purchased from Peprotech. Millipore Biomax-100K NMWL filter device (UFV2BHK40) was
purchased from Millipore. CMV-IRES-hrGFP/AAV system was purchased from Stratagene and the p3xFLAG-myc-CMV-23 expression vector from Sigma. pLVX-shRNA2-zsGreen1, Lenti-X 293T cells, and Xfect
transfection reagent were purchased from Clontech. OxiSelect Protein Carbonyl Immunoblot Kit was purchased from Cell Biolabs. All other chemicals
of reagent grade were from Sigma Chemicals or Merck.

Results

␣-Synuclein and Nox1 increases in human dopaminergic
neurons after PQ treatment
To evaluate the effects of PQ treatment on ␣-synuclein and Nox1
expression in human dopaminergic neurons, human ventral
mesencephalic neuronal progenitor cell line, ReNcell VM, was
used (Donato et al., 2007). We first differentiated ReNcell VM
into human midbrain neurons. After differentiation for 14 days,

the obtained cultures were immunopositive for Tuj-1, a neuronspecific class III ␤-tubulin. Moreover, the majority (80%) of differentiated cells were TH positive, a specific marker of dopaminergic
neuron, with an increased level of TH protein compared with undifferentiated cells (Fig. 1A). The effects of PQ on expression of
␣-synuclein and Nox1 were evaluated on these differentiated human
dopaminergic cells. We observed that differentiated dopaminergic
neurons express ␣-synuclein, which increases over time under PQ
treatment (Fig. 1B). Similarly, low basal level of Nox1 was highly
elevated by PQ treatment, as shown by immunocytochemistry and
Western blot analyses (Fig. 1C).
Overall, the results indicate that ␣-synuclein may be a key
player in PQ-mediated dopaminergic neuronal toxicity. Moreover, the result also suggests that Nox1 may have an important
role in the mechanism of human dopaminergic neurodegeneration as induced by PQ.
Nox1 knockdown significantly reduces PQ-induced
␣-synuclein expression and aggregation in dopaminergic cells
To further study the role of Nox1 in ␣-synucleinopathy caused by
PQ in dopaminergic cells, the rat dopaminergic neuronal cell
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Figure 5. Increase in ␣-synuclein and lipid peroxidation in the SN of rats administered with
PQ. A, Representative immunoblot and quantitative analysis of ␣-synuclein protein levels.
␣-Synuclein protein was determined in the total lysates of SN tissues of rats injected with
vehicle or PQ by immunoblot analysis. ␤-Actin was used as an internal control. PQ significantly
increased ␣-synuclein protein levels, which were quantified using Quantity One software and
normalized against ␤-actin. B, C, Representative photomicrographs of ␣-synuclein (B) and
4HNE (C) immunostaining in the SN of rats treated with vehicle or PQ. Data are shown as the
mean ⫾ SEM. Statistical analysis was performed using the Student’s t test; **p ⬍ 0.01. Scale
bars: 50 m.

line, N27 cells, was investigated. PQ significantly increased the
levels of ␣-synuclein expression. We observed 55 and 61% increases of ␣-synuclein protein levels in N27 cells exposed to 800
M PQ for 8 and 24 h, respectively. When exposed to a 1000 M
dose of PQ, an increase of 60 and 27%, respectively, for 8 and 24 h
incubation times was detected (Fig. 2 A). Immunocytochemical
evaluation showed that ␣-synuclein aggregation was also induced
by PQ. As shown in Figure 2 B, we could see increased immunoreactivity for ␣-synuclein in cultures treated with PQ, and, moreover, a pattern of aggregated ␣-synuclein was observed in treated
cultures, which was not detected in the untreated ones (Fig. 2 B,
arrowheads). The quantification of aggregated ␣-synuclein-positive
cells revealed an increase of ␣-synuclein aggregation in cultures exposed to PQ compared with the control. As shown in Figure 2D
(open bars), a statistical increase of 62 and 64% in aggregation was
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Figure 6. Increase in Nox1 protein levels in the SN of rats injected with PQ. A, Representative
immunoblot and quantitative analysis of Nox1 protein levels. Nox1 protein was determined in
the total lysates of SN tissues of rats injected with vehicle or PQ by immunoblot analysis. ␤-Actin
was used as an internal control. PQ significantly increased Nox1 protein, which was quantified
using Quantity One software and normalized against ␤-actin. B, Representative photomicrographs of Nox1-immunoreactivity in the SN sections of rats injected with vehicle or PQ. Nox1
immunoreactivity in the SN was increased in PQ-injected animals compared with vehicle. The
result is expressed as percentage of vehicle. Data are shown as the mean ⫾ SEM. Statistical
analysis was performed using the Student’s t test; **p ⬍ 0.01. Scale bars: 50 m.

found in cultures exposed for 24 h to 800 and 1000 M PQ, respectively. To confirm the effect of PQ in ␣-synuclein aggregation, we
have further evaluated the levels of ␣-synuclein resistant to PK digestion, since it was previously reported that ␣-synuclein aggregates
are resistant to limited PK digestion (Neumann et al., 2002). As
shown in Figure 3A, N27 cells exposed to PQ depict higher PKresistant ␣-synuclein immunoreactivity, an indicator of higher
␣-synuclein aggregation. We have further evaluated ␣-synuclein aggregation by investigating the levels of A11 immunoreactivity in untreated and PQ-treated N27 cell, as the anti-A11 oligomer antibody
was previously reported to efficiently detect ␣-synuclein aggregation
(Winner et al., 2011). Figure 3B shows high A11 immunoreactivity
in cultures exposed to PQ when compared with the controls, clearly
indicating increased ␣-synuclein aggregation induced by PQ. As expected, this group of results infers that PQ induces increased levels of
␣-synuclein expression as well as aggregation.
To explore the contribution of Nox1 in the changes of
␣-synuclein induced by PQ, we knocked down Nox1, using
lentivirus-mediated Nox1 shRNA overexpression (shNox1ZsGreen), and exposed N27 cells to PQ. The results showed that
PQ-induced ␣-synuclein aggregation was lower in cells overexpressing Nox1 shRNA (Fig. 2C). After quantifying the number of
cells depicting both shNox1-ZsGreen and ␣-synuclein aggre-
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gates, no statistical differences were found
between untreated and PQ-treated cultures as shown in Figure 2D (solid bars).
The same result was found when analyzing
A11 immunoreactivity in those cells. As
shown in Figure 3C, shNox1-ZsGreenpositive cells clearly had lower immunoreactivity for A11 compared with shNox1ZsGreen-negative cells.
Next, we sought to understand if Nox1
has a role only in the expression pathway of
␣-synuclein leading to protein increase and
subsequent aggregation, or if it was also acting directly in its aggregation capability.
Flag-tagged wild-type (WT) ␣-synuclein
and shNox1-ZsGreen were overexpressed
in N27 cells, and then cells were exposed to
PQ. Strong cytoplasmic aggregation was
induced by PQ treatment as detected by
anti-flag immunostaining (Fig. 4 A). A significant 2.5-fold increase of aggregation was
observed in cells exposed to PQ when compared with control cells (Fig. 4C, open bars).
Furthermore, when aggregation was analyzed in shNox1-ZsGreen-positive cells exposed to PQ, aggregation levels were not
statistically different from control cells (Fig.
4C, solid bars). Aggregation was decreased
by a 2.5-fold in shNox1-ZsGreen-positive
cells (Fig. 4B, arrow) when compared with
shNox1-ZsGreen-negative cells (Fig. 4B, arrowhead) for both concentrations of PQ
(Fig. 4B,C).
Altogether the above results are highly
suggestive that Nox1 is an important intermediary in regulation of both expression
and the aggregation process of ␣-synuclein
in dopaminergic cells stressed with PQ.

Figure 7. Selective Nox1 targeting by AAV-mediated Nox1 knockdown in the rat SN. A, AAV2 viral particles and PQ injection
paradigm diagram. To knockdown Nox1 in the SN, AAV2 particles harboring Nox1 shRNA were stereotaxically injected into the SN.
PQ intraperitoneal injections were performed 4 weeks after AAV2 delivery. Rats were divided into four groups. Group vector ⫹
vehicle: stereotaxic injection of AAV2 particles containing GFP vector and then vehicle (saline) intraperitoneal injection; group
vector ⫹ PQ: stereotaxic injection of AAV2 particles containing GFP vector and then PQ intraperitoneal injection; group shNox1 ⫹
PQ: stereotaxic injection of AAV2 particles harboring Nox1 shRNA-GFP and then PQ intraperitoneal injection; and group shNox1 ⫹
vehicle: stereotaxic injection of AAV2 particles harboring Nox1 shRNA-GFP and then vehicle intraperitoneal injection. Animals were
given a total of four intraperitoneal injections of either vehicle or PQ (10 mg/kg b.w.) every 2 d. All groups were killed 5 d post last
injection. B, Representative immunoblot and quantitative analysis of Nox1 protein determined in total lysates of rat ipsilateral SN
tissues. ␤-Actin was used as an internal control. Nox1 protein levels were quantified using Quantity One software and normalized
against ␤-actin. The results are expressed as percentage of vector ⫹ vehicle. Data are shown as the mean ⫾ SEM. Statistical
analysis was performed using one-way ANOVA followed by Bonferroni’s multiple-comparison test; *p ⬍ 0.05, **p ⬍ 0.01, and
***p ⬍ 0.001. (C) Representative photomicrographs of Nox1-immunoreactivity in the SN sections of the contralateral and ipsilateral sides of brain sections. Scale bars, 50 m.

PQ intraperitoneal injection causes
increases in ␣-synuclein and Nox1
protein level as well as oxidative stress in the rat SN
To validate the significance of our in vitro results, we moved
forward to in vivo studies, using a PQ-inducing rat model of PD.
Our first observations showed that PQ injection in rats induced
an increase of 50% in ␣-synuclein protein levels in the SN as
determined by Western blot (Fig. 5A). ␣-Synuclein immunoreactivity in the SN was also increased after PQ administration, as
shown in Figure 5B. The involvement of Nox1 in PQ-mediated
dopaminergic cell death in mice was reported in a previous study
of our group (Cristóvão et al., 2009). In the present study, PQ
insult also induced increased Nox1 protein level in the rat SN. As
shown in Figure 6A, animals exposed to PQ showed 58% higher
levels of Nox1 protein than the group treated with vehicle. The upregulation of Nox1 in the SN of rats injected with PQ was further
confirmed by immunohistochemistry as shown in Figure 6B.
Nox enzymes are responsible for ROS production; we then
evaluated if increases in Nox1 were also accompanied by increased oxidative stress markers in rat tissues exposed to PQ. As
depicted in Figure 5C, an increase in 4-HNE immunoreactivity, a
well established maker for lipid peroxidation, was found in the
SN of rats treated with PQ compared with rats treated with vehicle. The above results are in accordance with the ones observed in

vitro, and emphasize that under PQ insult, ␣-synuclein, Nox1,
and oxidative stress may act as partners to enhance dopaminergic
neurodegeneration.
The establishment of the rat model used in the present work
was based on our previous reported results showing in mice the
loss of dopaminergic neurons in the SN after PQ exposure (Cristóvão et al., 2009).
The specific knockdown of Nox1 reduced rat dopaminergic
neuronal loss induced by PQ
To investigate the role of Nox1 in oxidative stress, dopaminergic
neuronal death, and ␣-synuclein expression and aggregation
changes induced by PQ in rats we achieved Nox1 knockdown in
the SN by using AAV-mediated Nox1 shRNA overexpression.
Nox1 knockdown was achieved by stereotaxic delivery of AAV2
particles into the rat SN. PQ intraperitoneal injections were performed 4 weeks after the AAV2 injection, as depicted in Figure
7A. AAV2 containing GFP vector was used as a negative control.
To verify Nox1 knockdown efficiency, Nox1 levels in the SN of
each group of animals were investigated by Western blot and
immunohistochemistry analysis. Nox1 knockdown in the SN significantly reduced PQ-mediated Nox1 increases (Fig. 7 B, C). As

Cristóvão et al. • Nox1 Contribution for ␣-Synucleinopathy

J. Neurosci., October 17, 2012 • 32(42):14465–14477 • 14473

Figure 8. Nox1 knockdown reduced SN dopaminergic neuronal death induced in rats administered with PQ. A, Representative photomicrographs of TH immunostaining and quantitative analysis
of TH-positive dopaminergic neurons in the SN of rats after Nox1 knockdown. Representative photomicrographs of TH immunoreactivity in the SN of the contralateral and ipsilateral sides of brain
sections of the four experimental groups. TH-positive neurons in the ipsilateral side were stereologically counted. B, Representative immunoblot and quantitative analysis of TH protein levels. TH
protein was determined in total lysates of the rat’s SN tissues in the ipsilateral side by immunoblot analysis. ␤-Actin was used as an internal control. TH protein levels were quantified using Quantity
One software and normalized against ␤-actin. C, Representative photomicrographs of 4-HNE immunostaining in the SN of the contralateral and ipsilateral sides of brain sections of rats from shNox1
⫹ PQ group. Scale bars, 50 m. D, E, Immunoblot (D) and quantitative analysis (E) of protein carbonyl levels determined in total lysates of rats’ ipsilateral SN tissues. ␤-Actin was used as an internal
control. The results are expressed as percentage of vector ⫹ vehicle. Data are shown as the mean ⫾ SEM. Statistical analysis was performed using one-way ANOVA followed by Bonferroni’s
multiple-comparison test; *p ⬍ 0.05, **p ⬍ 0.01, and ***p ⬍ 0.001.

shown in Figure 7B, animals treated with vector ⫹ PQ showed statistically higher levels of Nox1 protein (70%) compared with animals treated with vector ⫹ vehicle. Compared with animals treated
with vector ⫹ PQ, animals treated with shNox1 ⫹ PQ showed a 40%
decrease in Nox1 protein levels in the SN (Fig. 7B). Nox1 levels in the
SN of each group of animals were also investigated by immunohistochemistry, confirming the decrease in Nox1 immunoreactivity in
the SN of animals exposed to Nox1shRNA ⫹ PQ compared with the
ones exposed to vector ⫹ PQ (Fig. 7C). These results confirmed that
AAV-mediated Nox1 knockdown in vivo significantly reduced PQmediated increase in Nox1 level, validating our knockdown method.
To investigate the contribution of Nox1 to the dopaminergic
neurotoxicity induced by PQ in each group of animals, the levels
of TH protein in the SN were investigated by Western blot and
the numbers of TH-positive dopaminergic neurons in the substantia nigra pars compacta were obtained by stereological analysis. Administration of vector ⫹ PQ significantly reduced TH
protein levels to 65% compared with the control group injected
with vector ⫹ vehicle, while TH protein levels were recovered to
87% in the group in which Nox1 was knocked down before PQ
exposure (Fig. 8 B). The stereological count of TH-positive neu-

rons showed that Nox1 knockdown significantly reduced PQelicited dopaminergic neuronal loss from 37% in the group
treated with vector ⫹ PQ to 13% in the Nox1shRNA ⫹ PQ group
(Fig. 8 A). In addition, we found that Nox1 knockdown also reduced oxidative stress levels, as shown by the levels of lipid peroxidation and protein oxidation. Increased immunoreactivity of
4-HNE (Fig. 8C) and protein carbonyl (Fig. 8 D, E) in animals
treated with PQ was decreased in the Nox1shRNA ⫹ PQ group.
Protein carbonyl levels were significantly increased by 95% after
PQ exposure when compared with vector ⫹ PQ group, and reduced to 22% when Nox1 was knocked down (Fig. 8 E). These
results have shown that Nox1 knockdown reduced dopaminergic
neuronal death and oxidative stress induced by PQ, which was in
accordance with our two previous report observations showing
that the Nox system plays an important role in PQ- and
6-OHDA-mediated dopaminergic neurotoxicity.
Increased expression and aggregation of ␣-synuclein induced
by PQ relies on Nox1 protein in the rat SN
Herein, we sought to evaluate the involvement of Nox1 in the
effect of PQ on ␣-synuclein expression levels and aggregation in
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Figure 9. Nox1 knockdown reduced PQ-mediated ␣-synuclein increase in the SN dopaminergic neurons. A, Representative immunoblot and quantitative analysis of ␣-synuclein protein levels.
␣-Synuclein protein was determined in total lysates of the rats SN tissues in the ipsilateral side by immunoblot analysis. ␤-Actin was used as an internal control. ␣-Synuclein protein levels were
quantified using Quantity One software and normalized against ␤-actin. The results are expressed as percentage of vector ⫹ vehicle. Data are shown as the mean ⫾ SEM. Statistical analysis was
performed using one-way ANOVA followed by Bonferroni’s multiple-comparison test; *p ⬍ 0.05 and **p ⬍ 0.01. B, Representative photomicrographs of PK-resistant ␣-synuclein immunoreactivity in the ipsilateral SN of brain sections of the four experimental groups. Increased PK-resistant ␣-synuclein immunostaining observed in the vector ⫹ PQ group was significantly decreased by
Nox1 knockdown as observed in shNox1 ⫹ PQ group. Scale bars, 50 m.

vivo. We investigated ␣-synuclein, protein aggregation, and
ubiquitin levels in the SN of each group of animals by Western
blot, dot blot, and immunohistochemical analyses. We found
significant increases of 54, 68, and 43%, in ␣-synuclein, A11positive oligomers and ubiquitin protein levels, respectively, in
the vector ⫹ PQ-treated group when compared with the vector ⫹
vehicle group (Figs. 9A, 10 A, C). Moreover, Nox1 knockdown
reduced by 37, 50, and 43% the PQ-mediated ␣-synuclein, A11
oligomers, and ubiquitin levels, respectively, compared with the
vector ⫹ PQ (Figs. 9A, 10 A, C). To further evaluate in vivo the
effect of Nox1 knockdown on PQ-induced ␣-synuclein aggregation we have also investigated the levels of ␣-synuclein resistant
to PK digestion. We were able to observe an increase in PKresistant ␣-synuclein immunoreactivity in the rat SN exposed to
vector ⫹ PQ, but not in the vector ⫹ vehicle group. A significant
reduction in PK-resistant ␣-synuclein staining was observed in
the group in which Nox1 was knocked down before PQ injection
(Nox1shRNA ⫹ PQ) (Fig. 9B). Immunohistochemistry evaluations revealed a significant increase in the immunoreactivity of
A11 oligomers in the SN of rats exposed to PQ, which was decreased in the group exposed to PQ in which Nox1 was knocked
down (Fig. 10 B). The involvement of Nox1 in PQ-induced
changes in ubiquitin in the SN was also evaluated and the significant increase in ubiquitin immunoreactivity observed in the rat
SN exposed to vector ⫹ PQ was reversed by Nox1 knockdown
(Nox1shRNA ⫹ PQ) (Fig. 10 D). Together our results are highly
suggestive of an active role of Nox1 in ␣-synucleinopathy induced by PQ at transcriptional levels as well as post-translational
aggregation mechanism.

Discussion
In the present work, we perceive Nox1 as a crucial intermediary,
between an environmental factor responsible for oxidative stress
condition and ␣-synuclein transcriptional regulation and aggre-

gation. We provide evidence that suggests, under oxidative stress,
as induced by PQ, ␣-synuclein expression and aggregation levels
are increased, which can be ameliorated to normal by Nox1
knockdown. And most important, dopaminergic loss in the SN of
rats exposed to PQ can also be recovered by Nox1 knockdown,
suggesting that Nox1-derived ROS play a crucial role in
␣-synuclein pathology as along with dopaminergic neuronal
degeneration.
␣-Synuclein is a distinctive genetic factor in PD pathogenesis,
in which its alterations and mutations were linked to the development of the disease (Beyer et al., 2009; Cookson, 2009). Oxidative stress has also been largely mentioned as a strong
contributor to the development of the disease, and it has also
been involved in PQ-induced dopaminergic neurodegeneration
(Dexter et al., 1994; Alam et al., 1997; Zhang et al., 1999). Physiologically, ROS are generated as a byproduct of several biological
reactions from organelles like mitochondria, and Nox is the specialized system that produces ROS, but not as a byproduct (Sorce
and Krause, 2009), and our recent studies demonstrated that
Nox1 serves as a major contributing factor in dopaminergic neuronal degeneration in both 6-OHDA and PQ-mediated PD rodent models (Cristóvão et al., 2009; Choi et al., 2012). Our results
using ReNcell VM cultures, which have been previously validated
as an in vitro model of human dopaminergic neurons (Donato et
al., 2007; Wood-Kaczmar et al., 2008), showed an increase in
Nox1 level following PQ exposure (Fig. 1C). Nox1 and the oxidative stress marker were also found increased in rats exposed to
PQ (Figs. 5, 6). The involvement of Nox1 in the mechanism of
PQ-induced neurotoxicity was first demonstrated by our study,
suggesting that Nox1 is involved in oxidative stress and consequent dopaminergic neuronal death (Cristóvão et al., 2009).
More recently, we reported that Nox1-induced ROS also contributes to dopaminergic neurodegeneration induced by 6-OHDA
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identified in early onset familiar PD (Singleton et al., 2003; Chartier-Harlin et al.,
2004), leading to the view that WT protein
could cause PD in a dose-dependent manner. Although this fact fortifies the importance of the transcriptional regulation of
␣-synuclein, relatively few studies have focused on the role of oxidative stress in the
expression level and transcriptional control
of ␣-synuclein. This is at least partly due to
the lack of proper in vitro and in vivo model
systems that successfully demonstrate the
increased endogenous ␣-synuclein level.
Importantly, in the current work, both in
vitro and in vivo models showed significant
changes in ␣-synuclein expression under
PQ exposure. The levels of ␣-synuclein in
ReNcells and N27 cells cultures exposed to
PQ were prominently increased with time
(Figs. 1B, 2A), and significant increase in
␣-synuclein was also observed in the rat SN
exposed to PQ as well (Fig. 5). Previous observations have shown that PQ increases
␣-synuclein expression levels and aggregation (Uversky et al., 2001; Manning-Bog et
al., 2002), and that could be directly related
to PQ-derived ROS generation (Krishnan et
al., 2003). However, the molecular mechanism behind this effect is still elusive. Altogether these findings are suggestive of a
possible relationship between increased
ROS and the transcriptional regulation of
␣-synuclein, consistent with studies showing that toxic insults involving ROS production induce increased ␣-synuclein levels in
the SN (McCormack et al., 2005). In PC12
cells as well as in primary cortical neurons
from rat, it was demonstrated that
␣-synuclein expression in response to neurotrophins is regulated by the MAP/ERK
and PI3-K pathways (Clough and Stefanis,
2007; Clough et al., 2011), which are also
Figure 10. Nox1 knockdown reduced PQ-mediated A11 oligomers and ubiquitin increase in the SN dopaminergic neurons. known to be activated under oxidative stress
Representative immunoblot and quantitative analysis of A11 oligomers (A) and ubiquitin (C) levels determined in total lysates of conditions (Miller et al., 2009). This sugthe rats SN tissues in the ipsilateral side by immunoblot analysis. ␤-Actin was used as an internal control. A11 oligomer levels were gests a possible relationship between inquantified using Quantity One software and normalized against ␤-actin. The results are expressed as percentage of vector ⫹ creased ROS and transcriptional regulation
vehicle. Data are shown as the mean ⫾ SEM. Statistical analysis was performed using one-way ANOVA followed by Bonferroni’s of ␣-synuclein through these pathways. The
multiple-comparison test; *p ⬍ 0.05, **p ⬍ 0.01 Representative photomicrographs of A11 oligomers (B) and ubiquitin (D)
above idea reinforces our hypothesis that
immunoreactivity in the ipsilateral SN of brain sections of the three experimental groups. B, Bottom right shows higher magnifiNox1-ROS generation might be a key regucation of the respective boxed area shown in the right top. Scale bars, 50 m.
lator controlling ␣-synuclein expression.
Nevertheless, the effects of ROS in tran(Choi et al., 2012), a well known toxin used to mimic PD pathoscriptional regulation are broad, including epigenetic alterations
genesis in vitro and in vivo (Javoy et al., 1976; Terzioglu and
(Zawia et al., 2009), transcription factors binding regulation
Galter, 2008). We showed that the nuclear localization of Nox1 is
(Clough et al., 2009), or DNA damage (Turk et al., 1995). How
responsible for nuclear DNA damage and degeneration of dopaNox1-derived ROS regulates the transcription of ␣-synuclein reminergic neurons after 6-OHDA treatment. Altogether this evimains to be investigated.
dence emphasizes the importance of Nox1 as a crucial participant
In addition to the effect of PQ in ␣-synuclein expression levin dopaminergic neurodegeneration.
els, we also found that PQ increased the aggregation of
␣-Synuclein point mutations, A30P, A53T, and E46K, were
␣-synuclein (Figs. 2– 4) in N27 cells as well as in the rat SN,
found in the familial forms of early onset PD and they are responaccompanied with increased levels of ubiquitin (Figs. 9, 10C,D).
sible for the changes in ␣-synuclein aggregation properties
These findings are in agreement with previous reports showing
(Hardy et al., 2009). Interestingly, elevated expression of WT
increased ␣-synuclein aggregation in mice exposed to PQ
␣-synuclein due to the multiplications of SNCA has also been
(Manning-Bog et al., 2002). Based on this, we sought to enlarge
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our view of the disease paradigm and search for a potential relationship between Nox1 and ␣-synuclein aggregation. Nox1
knockdown achieved by viral delivery of shRNA against Nox1
significantly reduced ␣-synuclein aggregation in both in vitro and
in vivo. A large number of reports have similarly shown that
AAV-mediated shRNA delivery to the CNS for targeted knockdowns of specific genes can be achieved (Harper et al., 2005),
including two of our recent works (Choi et al., 2011, 2012). On
the other hand, the lentivirus system that delivers genes to cells
showed higher infection efficiency then AAV2, but with less specificity, and was able to infect divided and nondivided cells. In that
sense this system is more suitable for in vitro gene delivery using a
cell culture system containing only one type of cells. Lentivirusmediated Nox1 knockdown in N27 cells led to significant reduction in PQ-induced ␣-synuclein aggregation. Several methods
were used for this evaluation and we found clear evidence that
Nox1 is involved in the aggregation process of ␣-synuclein induced
by PQ (Figs. 2C,D, 3C, 4B,C). Importantly, Nox1 knockdown also
prevented aggregation of WT ␣-synuclein overexpressed, suggesting
that along with its involvement in the transcriptional regulation,
Nox1-induced ROS may also play a role in stabilizing the protein,
leading to aggregation of ␣-synuclein.
AAV2-mediated Nox1 knockdown in the rat SN was shown to
be effective not only in reducing Nox1 protein levels in the SN
(Fig. 7 B, C), but also in reducing oxidative stress (Fig. 8C) and
dopaminergic neuronal death (Fig. 8 A) induced by PQ. Nox1
knockdown induced a significant decrease in the total levels of
␣-synuclein expression (Fig. 9A) after PQ treatment, as well as a
decrease in ␣-synuclein aggregation, as demonstrated by a decrease in PK-resistant ␣-synuclein (Fig. 9B). A11 oligomers (Fig.
10 A, B) and ubiquitin (Fig. 10C,D) levels were also decreased,
indicating that PQ-mediated ␣-synuclein aggregation is partially
regulated by Nox1-derived ROS. These results are in agreement with
other studies, which demonstrate that cytoplasmic ␣-synuclein aggregations can be induced by various ROS generators, such as hydroxyl radicals and peroxynitrite (Butterfield and Kanski, 2001;
Matsuzaki et al., 2004). These metabolites are strong oxidants that
can promote not only nitration but also oxidation of ␣-synuclein,
favoring the stabilization of the protein polymer by forming stable
cross-linked ␣-synuclein aggregates (Alvarez et al., 1999; Hashimoto
et al., 1999; Souza et al., 2000).
In summary, our study provides strong evidence that Nox1 is
involved in the mechanism responsible for generation of PQmediated oxidative stress conditions implicated in increased
␣-synuclein expression and aggregation, and dopaminergic neurodegeneration in the PQ-treated rat model of PD. This work also
strengthens the possible relationship between oxidative stress
and ␣-synuclein pathology in PD, introducing Nox1 as a key
molecule that could serve as a good therapeutic target for PD and
others ␣-synucleinopathies.
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